VJHemOnc Podcast

Experts discuss the efficacy and safety of Celtisal as a potential treatment option for myeloma, challenges in treating refractory myeloma, the impact of Cartie treatment on patients' quality of life, and the role of minimal residual disease in clinical decision-making.

Experts discuss recent advances in CAR-T therapy and bispecific antibodies in the treatment of large B-cell lymphoma. Topics covered include sequencing these agents, bridging therapies, and managing toxicities and cytopenias after CAR-T therapy.

Experts discuss challenges of implementing CAR-T therapy in CLL, ongoing trials exploring combination approaches with CAR-T cells and BTK inhibitors, potential impact of a Trans-NCLL study, persistence of CAR-T cells and deep remissions observed with combination therapy, obstacles faced in CAR-T therapy for CLL, including patient response and tumor cell resistance, and optimistic outlook for future advancements in CAR-T therapy.

Therapeutic agents for MDS are being investigated in clinical trials. The management of anemia in lower-risk MDS and overcoming treatment failure in higher-risk disease are discussed. Exciting drugs for lower-risk MDS are presented, but challenges in high-risk MDS remain.

Experts discuss challenges in CAR-T therapy for AML, strategies to improve patient outcomes, integrating CAR-T cells into stem cell approach, targeting leukemia stem cells, challenges with T-cell fitness, impact of target antigens on T-cell exhaustion, collaboration, bias towards NK cells, optimism for improving leukemia treatment

Experts discuss the challenges and future outlooks of CAR-T therapy in acute lymphoblastic leukemia (ALL), including the potential effectiveness of Auto3, the need for randomized studies, optimizing dual targeting CAR-T therapy, and unifying data from different delivery methods and manufacturing techniques. They also explore reverse translation and the importance of target selection, car constructs, T cell attributes, and investigating the tumor microenvironment in optimizing patients for CAR T cell immunotherapy. Factors affecting selective expansion of CAR-T therapy in ALL patients, the influence of prior CD19-directed therapy, and the need for better products and a preclinical platform for measuring T cell function are also discussed. Lastly, they explore the dilemma of choosing between approved CAR-T products and experimental ones as frontline therapy, emphasize the importance of informed consent, and highlight the potential benefits of dual targeting in CAR-T therapy for ALL treatment.

World-leading experts in CAR-T therapy discuss updates on CAR-T therapy in lymphoma, including efficacy, durability of response, and real-world experience. They also discuss the potential role of bispecific antibodies, challenges related to patient access and manufacturing, and potential strategies in treating CAR-T therapy resistance.

Gareth Morgan and Pieter Sonneveld discuss reaching a cure for multiple myeloma and concepts that need to be addressed. They explore the use of target therapies and CAR-T therapy, the importance of response adapted therapy and concerns about maintenance therapy duration, and the significance of ongoing therapy and autologous stem cell transplant.

Experts discuss the role of stem cell transplantation in MPNs and the need for early transplantation. Considerations in selecting patients for transplant are covered, as well as challenges in transplantation for myelofibrosis. The potential changes to the role of transplantation with novel agents are explored, including the concept of disease modification in MPNs.

Irene Ghobrial and Paola Neri discuss the tumor microenvironment, immune microenvironment, and resistance mechanisms to targeted therapies in multiple myeloma. Topics include T cell fitness, checkpoint inhibitors, stromal cells, cytokines, chemokines, CAR T cells, IL-6, STAT-3 signaling pathways, therapy effects on immune system and tumor cells, post-therapy treatments, and understanding resistance mechanisms.